AstraZeneca may have provided incomplete efficacy data from latest Covid-19 trial: NIAID | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Friday
June 13, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
FRIDAY, JUNE 13, 2025
AstraZeneca may have provided incomplete efficacy data from latest Covid-19 trial: NIAID

Coronavirus chronicle

Reuters
23 March, 2021, 11:00 am
Last modified: 23 March, 2021, 12:29 pm

Related News

  • US Health Secretary Kennedy guts vaccine advisory committee
  • Govt plans to relocate country's first vaccine plant from Gopalganj to Munshiganj
  • Umrah pilgrims struggle with abrupt meningitis vaccination requirement amid shortage
  • Vaccination, early screening can prevent cervical cancer death for women
  • Study on Bangladeshi children confirms lasting impact of typhoid vaccine

AstraZeneca may have provided incomplete efficacy data from latest Covid-19 trial: NIAID

AstraZeneca said a day earlier that its Covid-19 vaccine developed with Oxford University was 79% effective in preventing symptomatic illness in a large trial in Chile, Peru and the United States

Reuters
23 March, 2021, 11:00 am
Last modified: 23 March, 2021, 12:29 pm
Vials labelled "Astra Zeneca COVID-19 Coronavirus Vaccine" and a syringe are seen in front of a displayed AstraZeneca logo, in this illustration photo taken March 14, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo
Vials labelled "Astra Zeneca COVID-19 Coronavirus Vaccine" and a syringe are seen in front of a displayed AstraZeneca logo, in this illustration photo taken March 14, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo

AstraZeneca Plc may have provided an incomplete view of efficacy data on its Covid-19 vaccine from a large scale US trial, a US health agency said Tuesday in a fresh setback for the shot.

The news comes just one day after interim data from the drugmaker showed better-than-expected results from the trial and casts doubt on its plan to seek US emergency use authorization for the vaccine in the coming weeks.

The vaccine developed with Oxford University was 79% effective in preventing symptomatic illness in a large trial in the United States, Chile and Peru, and, crucially, posed no increased risk of blood clots, according to the data.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

The Data Safety Monitoring Board (DSMB) has "expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data," the US National Institute of Allergy and Infectious Diseases (NIAID) said in a statement.

NIAID is headed by US infectious diseases expert Anthony Fauci and is part of the National Institutes of Health.

"We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible," it said.

AstraZeneca did not immediately respond to a Reuters request for comment.

Authorization and guidelines for use of the vaccine in the United States will be determined after thorough review of the data by independent advisory committees, the statement added.

Hailed as a milestone in the fight against the Covid-19 pandemic when it emerged as a vaccine contender last year, the AstraZeneca shot has been dogged by doubts over its efficacy, dosing regimen and possible side effects.

More than a dozen European countries, including Germany and France, halted use of the vaccine earlier this month after reports linked it to a rare blood clotting disorder in a very small number of people.

The latest trial data, which have yet to be reviewed by independent researchers, was set to give credence to the British shot after results from earlier, separate late-stage studies raised questions about the robustness of the data.

Fauci, who also serves as chief medical advisor to US President Joe Biden, said on Monday the US trial found no indication at all of the rare blood clots.

The latest data was based on 141 infections among 32,449 participants.

The shot has also been at the centre of a growing conflict between Brussels and London over so-called vaccine nationalism after a string of supply setbacks in Europe.

Vaccine efficacy / vaccine data / Vaccine / Coronavirus Vaccine / covid-19 vaccine / AstraZeneca Covid-19 Vaccine / Oxford-AstraZeneca vaccine / AstraZeneca vaccine / AstraZeneca's vaccine / US National Institute of Allergy and Infectious Diseases (NIAID)

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • BNP Acting Chairperson Tarique Rahman and Chief Adviser  Muhammad Yunus meet at Dorchester Hotel in London, UK on 13 June 2025. Photo: CA Press Wing
    CA Yunus, Tarique agree on election in February if preparations complete
  • BNP Acting Chairperson Tarique Rahman and Chief Adviser  Muhammad Yunus meet at Dorchester Hotel in London, UK on 13 June 2025. Photo: CA Press Wing
    'Historic' Yunus-Tarique meeting ends after nearly 1.5 hours of discussions on polls, other crucial issues
  • Rescuers work at the scene of a damaged building in the aftermath of Israeli strikes, in Tehran, Iran, June 13, 2025. Majid Asgaripour/WANA (West Asia News Agency) via REUTERS
    Tehran retaliates with 100 drones after Israel strikes Iran's nuclear facilities, kills military leaders

MOST VIEWED

  • Wreckage of a Boeing 787 Dreamliner showing part of its registration "VT-ANB" in Ahmedabad, India, June 12, 2025. REUTERS/Amit Dave
    Air India Dreamliner crashes into Ahmedabad college hostel, kills over 290
  • File Photo of Chief Adviser Muhammad Yunus: UNB
    Prof Yunus to receive Harmony Award from King Charles today
  • Bangladesh Bank Governor Ahsan H Mansur. TBS Sketch
    Bangladesh mulls settlements with tycoons over offshore wealth: BB governor tells FT
  • Railway seeks Tk2,000cr foreign loans to revive coach assembly, modernise workshops
    Railway seeks Tk2,000cr foreign loans to revive coach assembly, modernise workshops
  • UK Prime Minister Keir Starmer, Chief Adviser Muhammad Yunus
    Disclosure of unconfirmed Yunus-Starmer meeting shows ‘diplomatic imprudence’: Analysts
  • Brother sues Latifur's daughter, widow over alleged forgery to seize control of Transcom
    Brother sues Latifur's daughter, widow over alleged forgery to seize control of Transcom

Related News

  • US Health Secretary Kennedy guts vaccine advisory committee
  • Govt plans to relocate country's first vaccine plant from Gopalganj to Munshiganj
  • Umrah pilgrims struggle with abrupt meningitis vaccination requirement amid shortage
  • Vaccination, early screening can prevent cervical cancer death for women
  • Study on Bangladeshi children confirms lasting impact of typhoid vaccine

Features

Among pet birds in the country, lovebirds are the most common, and they are also the most numerous in the haat. Photo: Junayet Rashel

Where feathers meet fortune: How a small pigeon stall became Dhaka’s premiere bird market

1d | Panorama
Illustration: Duniya Jahan/ TBS

Forget Katy Perry, here’s Bangladesh’s Ruthba Yasmin shooting for the moon

2d | Features
File photo of Eid holidaymakers returning to the capital from their country homes/Rajib Dhar

Dhaka: The city we never want to return to, but always do

4d | Features
Photo collage shows political posters in Bagerhat. Photos: Jannatul Naym Pieal

From Sheikh Dynasty to sibling rivalry: Bagerhat signals a turning tide in local politics

6d | Bangladesh

More Videos from TBS

'Historic' meeting between Yunus and Tarique underway in London

'Historic' meeting between Yunus and Tarique underway in London

1h | TBS Today
Iran warns Israel of severe retaliation

Iran warns Israel of severe retaliation

2h | TBS World
Global oil prices soar

Global oil prices soar

3h | TBS World
What did Iran say in response to the Israeli attack?

What did Iran say in response to the Israeli attack?

3h | TBS World
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net